Table 1.

Randomized clinical trials with TRA in ITP

Author / study	Patients	Control	New therapy	Na	Response rateb (HR, OR)	Durable responsec
Bussel, 2007	chronic ITP,	placebo	Elt 50d	59	11 vs. 70e
TRA 100773A [37]	2nd or 3rd line				p < 0.001
Bussel, 2007	chronic ITP,	placebo	Elt 75	57	11 vs. 81
TRA 100773A [37]	2nd or 3rd line				p < 0.001
Bussel, 2009	chronic ITP,	placebo	Elt 50	114	16 vs. 59
TRA 100773B [38]	2nd or 3rd line				p < 0.0001
Cheng, 2011	chronic ITP,	placebo	Elt 50	197	28 vs. 79	10 vs. 60
RAISE [39]	2nd or 3rd line				OR 8,20f
p < 0.0001	p < 0.0001
Kuter, 2008 [40]	chronic ITP
after splenectomy	placebo	Rom	63	0 vs. 79 p < 0.0001	0 vs. 38 p = 0.0013
Kuter, 2008 [40]	chronic ITP no splenectomy	placebo	Rom	62	14 vs. 88
p < 0.0001	5 vs. 56
p < 0.0001
Kuter, 2010 [41]	chronic ITP, no splenectomy	placebo	Rom	234	26 vs. 81 OR 2.3f p < 0.001

HR = Hazard ratio; OR = odds ratio; Elt = eltromboag; Rom = romiplostim.

^aNumber of patients.

^b% of patients with ≥50,000/µl at the prespecified endpoint.

^c% of patients with ≥50,000/µl for at least 6 weeks.

^dNumber indicates the dose in mg.

^eResults for controls vs. results for new therapy.

^fHR or OR for new therapy.